Regen BioPharma Advances Towards Breast Cancer Immunotherapy
Written by Cecile AUGUST 5, 2014 in Featured on App, R&D, Therapeutic Vaccines with 4 Comments
Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine
Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine
On the 1st of August 2014, Regen BioPharma reported on progress on its therapeutic cancer vaccine dCellVax, which stimulates the immune system of patients to selectively kill tumors.
Thomas Ichim, the Chief Scientific Office of Regen BioPharma, said in a statement that ‘we are please to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells, which is a major step forward in development of our Investigational New Drug (IND) application to the FDA. ‘
The original developer of the technology behind dCellVax is Dr.Wei-Ping Min, a Professor at the University of Western Ontario. The patent for this therapy was originally assigned to Regen BioPharma by Dr.Min, who used dendritic cells whose genes were silenced in order to induce regression of breast cancer tumors in animal models.
The vaccine is based on extracting blood from patients , growing dendritic cells from it and then genetically modifying them to become resistant to cancer’s immune suppressive activity. In many cancers, the production of indolamine 2,3 deoxygensae (IDO) enzyme is stimulated, which dampens the immune system. Dendritic cells normally stimulate the immune system, but when they express IDO in cancer, they suppress the immune system. If a vaccine can be developed that provides an effective dose of dendritic cells silenced for IDO, then normal anti-tumor responses can be stimulated once again.
The CEO of Regen BioPharma, David Koos, has said that ‘we are optimistic that this data will lead to advancement of dCellVax into clinical trials,’
We are optimistic that this data will lead to advancement of dCellVax into clinical trials
David Kroos, CEO of Regen BioPharma
The CEO of the company also notes that ‘the smooth translation of this university acquired intellectual property into a commercial setting further supports the Regen BioPharma model of rapidly advancing patents that are sitting unnoticed in the technology transfer offices of universities.’
Only time will tell if the vaccine’s technology, which has thus far only been tested on animals, is safe for humans in the battle against cancer.
Read more about it here: Regen BioPharma Provides Update on dCellVax Breast Cancer Immunotherapy
News 
Market Data 
Discover 
